Janice I Tetherow, MA,CPC,LMHP,NCC Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 442 N Cherry St, Valentine, NE 69201 Phone: 402-376-1000 |
Carrie Ann Reinders, LPC-MH Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 515 N Hall St, Valentine, NE 69201 Phone: 402-389-0339 |
News Archive
A proposal to cut the Medicare End-Stage Renal Disease (ESRD) Program by nearly 10% may have unintended consequences for people on dialysis. "More than 20 million Americans have kidney disease, and the Medicare ESRD program provides lifesaving care to nearly 400,000 beneficiaries with kidney failure," said Bruce A. Molitoris, MD, FASN, President of the American Society of Nephrology (ASN).
Merck/Schering-Plough Pharmaceuticals today announced the regulatory approval of INEGYTM (ezetimibe/simvastatin) in Germany for the treatment of elevated cholesterol (hypercholesterolemia). INEGY is the first product to reduce low-density lipoprotein cholesterol (LDL-C or ‘bad' cholesterol), along with diet and exercise, through dual inhibition by inhibiting cholesterol production in the liver and absorption in the intestine. The approval of INEGY in Germany represents the first approval in Europe for ezetimibe/simvastatin tablets and the first step in seeking marketing approval throughout the European Union (EU) under the EU's mutual recognition procedure.
Batu Biologics announced today FDA development plans for its patent-pending lead product, ValloVax, a cancer immunotherapeutic "vaccine" that specifically targets the tumor blood vessels (endothelium).
CIGNA International announced it will develop and offer individual Private Medical Insurance (PMI) to respond to the emerging needs of customers around the globe. CIGNA International – a world leader in global life, accident and health insurance and global expatriate benefits – will provide local PMI for citizens in countries outside the United States as well as to individual expatriates and high net worth individuals.
The Centers for Medicare & Medicaid Services announces it has fixed the glitch that took down the website where doctors and hospitals can review information about payments from drug and device makers. Meanwhile, The New York Times looks at how costly compounded medicines are drawing the ire of health insurers, and a U.K. agency recommends the government pay for a costly new hepatitis treatment.
› Verified 8 days ago